Archive for the ‘Urology / Nephrology’ Category
Sunday, April 13th, 2008
UroToday.com - A group from the Medical University of Vienna, Austria presented their data on high-intensity focused ultrasound (HIFU) for the treatment of small renal tumors. They showed data that HIFU works by a targeted homogeneous ablation of renal tissue. The objective of their clinical phase I study was to ...
Posted in Urology / Nephrology | No Comments »
Sunday, April 13th, 2008
UroToday.com - Updated results and analysis of prognostic factors from a phase III randomized trial.Sunitinib malate has demonstrated statistically superior progression-free survival (PFS) and objective response rate (ORR) compared with IFN-alfa (IFN-α) in an international, randomized phase III trial of first-line therapy in patients (pts) with metastatic renal cell carcinoma ...
Posted in Urology / Nephrology | No Comments »
Sunday, April 13th, 2008
UroToday.com - Sorafenib 400 mg b.i.d. has shown anti-tumor activity and favorable tolerability in patients with metastatic renal cell carcinoma (RCC), allowing investigation of more intensive drug administration regimens. This titration study allowed individual patients to escalate to higher doses of sorafenib. Trial endpoints included response rate (RR), progression-free survival ...
Posted in Urology / Nephrology | No Comments »
Sunday, April 13th, 2008
UroToday.com - Sunitinib malate is an oral, multi-targeted tyrosine kinase inhibitor with direct anti-tumor and anti-angiogenic activities, internationally approved for the first-line treatment of advanced RCC. This international, open-label trial was undertaken to provide sunitinib to patients with advanced RCC who might benefit from therapy, but who had no access ...
Posted in Urology / Nephrology | No Comments »
Sunday, April 13th, 2008
UroToday.com - Long-term efficacy results of EORTC GU group study 30911 comparing epirubicin, bacilus calmetteguerin (BCG), and BCG plus isoniazid in patients with intermediate and high risk stage Ta T1 papillary carcinoma of the bladderDr. Sylvester from the EORTC presented a study on the benefit of BCG relative to chemotherapy ...
Posted in Urology / Nephrology | No Comments »
Sunday, April 13th, 2008
UroToday.com - Dr. Gunnar Aus (Gothenburg) presented an update on the EAU guidelines. Guidelines are related to evidence-based medicine (EBM) which is the "conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients" (Sackett, DL, 1996, BMJ). However, guidelines are slightly different ...
Posted in Urology / Nephrology | No Comments »
Sunday, April 13th, 2008
UroToday.com - Dr. Gschwend (Munich) presented a State-of-the-Art lecture on LN disease in renal and bladder cancers. He began with bladder cancer and that staging correlates with disease specific survival. The stage also correlates with the likelihood of positive LN. Dr. Gschwend stated that surgical LA is the standard for ...
Posted in Urology / Nephrology | No Comments »
Sunday, April 13th, 2008
UroToday.com - Dr. Porta presented this talk on behalf of the sorafenib (Sor) TARGET clinical trial group. It is a follow-up on the significant progression-free survival (PFS) benefit for sorafenib (Sor) versus placebo (P) as seen in a large multicenter Phase III trial (TARGET) in patients (pts) with advanced RCC. ...
Posted in Urology / Nephrology | No Comments »
Sunday, April 13th, 2008
UroToday.com - On behalf of the Spanish CUETO study group, Dr. Martinez-Pineiro presented multicenter data on a new BCG schedule with the intent to lower toxicity. Patients in the study had TaG3 or T1G3 transitional cell carcinoma of the bladder and/or carcinoma in situ. Within 3 weeks following biopsy of ...
Posted in Urology / Nephrology | No Comments »
Sunday, April 13th, 2008
UroToday.com - Dr. Michael Jewett (Toronto) presented the SIU lecture on detection and mapping regional lymph nodes (LN) in genitourinary cancer. He addressed the importance of LN in staging and therapy of GU cancers. Staging is prognostic and sets the scenario for adjuvant therapy. Lymphadenectomy (LA) is therapeutic and should ...
Posted in Urology / Nephrology | No Comments »